331 related articles for article (PubMed ID: 33976200)
1. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
Teng KW; Tsai ST; Hattori T; Fedele C; Koide A; Yang C; Hou X; Zhang Y; Neel BG; O'Bryan JP; Koide S
Nat Commun; 2021 May; 12(1):2656. PubMed ID: 33976200
[TBL] [Abstract][Full Text] [Related]
2. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
3. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.
Wu PK; Hong SK; Starenki D; Oshima K; Shao H; Gestwicki JE; Tsai S; Park JI
Oncogene; 2020 May; 39(21):4257-4270. PubMed ID: 32291414
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.
Shin SM; Choi DK; Jung K; Bae J; Kim JS; Park SW; Song KH; Kim YS
Nat Commun; 2017 May; 8():15090. PubMed ID: 28489072
[TBL] [Abstract][Full Text] [Related]
5. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
6. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
7. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
8. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
10. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
11. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
[TBL] [Abstract][Full Text] [Related]
12. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors.
Kazi A; Xiang S; Yang H; Delitto D; Trevino J; Jiang RHY; Ayaz M; Lawrence HR; Kennedy P; Sebti SM
Nat Commun; 2018 Dec; 9(1):5154. PubMed ID: 30514931
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
14. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
15. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
16. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
17. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
[TBL] [Abstract][Full Text] [Related]
18. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
19. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
[TBL] [Abstract][Full Text] [Related]
20. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
